HOME > News Releases > The latest news 2011   December 2, 2011 Research Finding Report on and Academic Society Award for Functional Peptide, “COSMEPEPTIN (TM)” - Findings on COSMEPEPTIN (TM) reported at Anti-Aging Festa 2011; Anti-Aging Medicine Practices - November 25, 2011 Development of a Novel Molecular Therapy Agent against Joint Contracture was Adopted as A-STEP by JST - Development of a Novel Molecular Therapy Agent using “Decoy Nucleotides”- November 24, 2011 Research Findings concerning Anti-Wrinkle, Anti-Sagging and Anti-Microbial Actions by Functional Peptides, “COSMEPEPTIN (TM)” - Findings on COSMEPEPTIN (TM) Reported at Nikkei BP Health & Beauty Seminar - September 26, 2011 Second Prize in the Year 2011 Intellectual Property Award by Osaka Prefecture - HGF (Hepatocyte Growth Factor) Gene Therapy against Peripheral Arterial Obstruction - September 22, 2011 The Developmental Status of Anticancer Drug, HVJ-E (GEN0101/TSD-0014) by GenomIdea, a Subsidiary of AnGes MG September 12, 2011 Completion of RAC Review by NIH - Protocol for U.S. Phase III Clinical Trial on “Collategene(TM),” Therapeutic Agent for Ischemic Disease - September 1, 2011 AnGes MG's Project Received a Support Grant by the Ministry of Economy, Trade and Industry -“Development and Improvement of Medical Device for Decubitus Ulcer to Solve Infection Problem”Project - August 22, 2011 Establishing a Subsidiary in the Business Field of Healthcare August 10, 2011 Co-Development of Novel Cosmetic and Healthcare Products, Using Functional Peptides - A Basic Agreement with St. Louis International, Inc. Concluded - August 9, 2011 Medical-Use Patent for Ets-1 Granted in the U.S. - Intended for Angiogenesis/Gene Therapy Using Transcription Factor, Ets-1 - August 8, 2011 New Appointment of Corporate Officer August 8, 2011 GenoLac BL Co. and AnGes MG, Inc. Concluded a Basic Agreement - Joint Development of Therapeutic Vaccines for HPV - August 4, 2011 The Japanese Circulation Society Adopted a Research Study on Endovascular Treatment Using NF-kB Decoy as Translational Research Promotion Project - Study Group at Tokyo Medical and Dental University and Others - June 22, 2011 Substance Patent for Novel Peptide Granted in Japan - A Patent Covering Polypeptide Having Both Angiogenic and Antimicrobial Activity - June 15, 2011 GenomIdea, a Subsidiary of AnGes MG, and TSD Japan Sign Contract for Joint Conduct of Licensing Activities - Strengthen Licensing Activities toward Global Development of GEN0101/TSD-0014 - June 13, 2011 Medical-Use Patent for GEN0101/TSD-0014 (HVJ-E) Granted in Japan - Intended for Anti-Cancer Drugs - May 24, 2011 Substance Patent for NF-κB/E2F Chimera Decoy-Oligonucleotide Granted in Europe - Covering new type decoy oligodeoxynucleotides which can inhibit multiple transcription factors - March 31, 2011 MEDRx Co. Ltd. and AnGes MG, Inc. Entered into a License Agreement - Improvement of the skin permeability of NF-κB decoy oligodeoxynucleotide - March 24, 2011 Medical Journal Publication of Results of Study on Collategene (HGF gene therapy product) in Japan - Data of Open-Label Study Targeting Buerger’s Disease - March 15, 2011 Notices Regarding the Effects of the Tohoku Earthquake and Tsunami March 10, 2011 Medikit and AnGes MG Signed a Memorandum of Understanding for Development, Manufacturing, and Distribution of a Novel Medical Device - A New Type of Drug-Coated PTA Balloon Catheter - March 2, 2011 New Medical-Use Patent for HGF Gene Therapy Granted in Japan - For Treatment or Prophylaxis of Brain Infarction - February 21, 2011 Industry-Academia Joint R&D Project on “Oral Drug Delivery System (DDS) Using PLGA Nanoparticle Technology Containing Nucleic Acid” That Enables Definitive Therapy of Intractable Inflammatory Bowel Disease, Adopted as “Regional Innovation R&D Project”, a Strategic Technology Aid Program February 16, 2011 AnGes MG’s Founder Receives the “Japan Venture Awards 2011” - Awarded for excellency in the founding of venture businesses and management - February 9, 2011 Medical-Use Patent for HGF Gene Granted in Japan - Covering the combination use of hyperbaric oxygen therapy with angiogenesis factor gene therapy in order to improve therapeutic effects - January 11, 2011 Medical Journal Publication of Data of US Phase II Study of Collategene (HGF plasmid) January 6, 2011 Development of Novel Disinfectants Utilizing Antimicrobial Peptides Cure-Peptin(R) Joint R&D with Kinshukai Group, Japan’s Largest Group of Hospitals and Nishiki Corporation January 4, 2011 Medical Journal Publication of Long-Term Data of Japanese Phase I/II Studies of Collategene (HGF plasmid) - Clinical Study for Peripheral Vascular Diseases in Osaka University -

Contact | Site Map | Site Policy | Privacy Policy